##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 59 Download : 58

##plugins.themes.academic_pro.article.main##

Abstract

Pulmonary fibrosis, a progressive and debilitating lung disease, has long been the focus of extensive research due to its impact on respiratory function. However, emerging studies have unveiled a lesser-explored facet of this disease: its influence on extrapulmonary organs. This article delves into the uncharted territory of the impact of pulmonary fibrosis on the structure of the small intestine. Through a comprehensive review of experimental data and clinical observations, it becomes evident that pulmonary fibrosis is not merely confined to the lungs. Rather, it exerts a multifaceted influence on the small intestine, leading to structural alterations, impaired nutrient absorption, and a cascade of systemic effects. Understanding this interplay between the lung and the intestine is pivotal for a holistic comprehension of pulmonary fibrosis and opens new avenues for therapeutic strategies targeting extrapulmonary manifestations

Keywords

Pulmonary Fibrosis Small Intestine Extrapulmonary Effects Gastrointestinal Structure

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Barnoev Akhtam Istamovich, & Khasanova Dilnoza Akhrorovna. (2023). Impact Of Pulmonary Fibrosis on The Structure of The Small Intestine. Texas Journal of Medical Science, 25, 80–82. https://doi.org/10.62480/tjms.2023.vol25.pp80-82
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., ... & Behr, J. (2018). Diagnosis of Idiopathic Pulmonary Fibrosis: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 198(5), e44-e68.
  2. Wynn, T. A. (2011). Integrating mechanisms of pulmonary fibrosis. The Journal of Experimental Medicine, 208(7), 1339-1350.
  3. Dickson, R. P. (2016). The microbiome and critical illness. The Lancet Respiratory Medicine, 4(1), 59-72.
  4. Waisman, A., Liblau, R. S., & Becher, B. (2017). Innate and adaptive immune responses in the CNS. The Lancet Neurology, 16(12), 947-956.
  5. Camelo, A., Dunmore, R., Sleeman, M. A., & Clarke, D. L. (2019). The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Frontiers in Pharmacology, 10, 375.
  6. Patterson, E. K., Yao, L., Robinson, L. S., Jones, B. V., D'Costa, S., R. (2018). Microbiome, and Disease in the Lung. Microorganisms, 6(4), 116.
  7. Song, C., Chen, L. X., & Gao, Y. Y. (2020). Intestinal dysbiosis in pulmonary diseases. Cellular and Molecular Life Sciences, 77(22), 4805-4816.
  8. Kreuter, M., Ehlers-Tenenbaum, S., Palmowski, K., Bruhwyler, J., Oltmanns, U., Muley, T., ... & Bonella, F. (2015). Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE, 10(3), e0110370.
  9. Wang, H., Li, T., Chen, S., Gu, Y., Ye, Z., Wang, Y., ... & Luo, J. (2021). The Gut-Lung Axis: A Novel Immune Route for Potential Treatment of Inflammatory Lung Disease. Frontiers in Pharmacology, 12, 736753.